Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
Arends EJ, Zlei M, Tipton CM, Cotic J, Osmani Z, de Bie FJ, Kamerling SWA, van Maurik A, Dimelow R, Gregan YI, Fox NL, Rabelink TJ, Roth DA, Sanz I, van Dongen JJM, van Kooten C, Teng YKO. Arends EJ, et al. Among authors: van maurik a. Rheumatology (Oxford). 2024 Sep 1;63(9):2387-2398. doi: 10.1093/rheumatology/keae286. Rheumatology (Oxford). 2024. PMID: 38775637 Free PMC article.
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. Among authors: van maurik a. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, Clark KL, Furie R, Groark J, Urowitz MB, van Vollenhoven R, Daniels M, Fox NL, Gregan YI, Henderson RB, van Maurik A, Ocran-Appiah JC, Oldham M, Roth DA, Shanahan D, Tak PP, Teng YO. Aranow C, et al. Among authors: van maurik a. Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512. doi: 10.1136/ard-2024-225686. Ann Rheum Dis. 2024. PMID: 39159997 Free PMC article. Clinical Trial.
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
McClure ME, Gopaluni S, Wason J, Henderson RB, Van Maurik A, Savage CCO, Pusey CD, Salama AD, Lyons PA, Lee J, Mynard K, Jayne DR, Jones RB; on behalf the COMBIVAS investigators. McClure ME, et al. Among authors: van maurik a. Trials. 2023 Mar 11;24(1):180. doi: 10.1186/s13063-023-07218-y. Trials. 2023. PMID: 36906660 Free PMC article.
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.
Jimenez-Royo P, Bombardieri M, Ciurtin C, Kostapanos M, Tappuni AR, Jordan N, Saleem A, Fuller T, Port K, Pontarini E, Lucchesi D, Janiczek R, Galette P, Searle G, Patel N, Kershaw L, Gray C, Ratia N, van Maurik A, de Groot M, Wisniacki N, Bergstrom M, Tarzi R. Jimenez-Royo P, et al. Among authors: van maurik a. Rheumatology (Oxford). 2021 May 14;60(5):2396-2408. doi: 10.1093/rheumatology/keaa624. Rheumatology (Oxford). 2021. PMID: 33221921 Free PMC article.
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B, van Maurik A, Inman D, Oliveira J, McLaughlin R, Gittelman RM, Roep BO, Gillard P, Hilbrands R, Gorus F, Mathieu C, Van de Velde U, Wisniacki N, Napolitano A. Keymeulen B, et al. Among authors: van maurik a. Diabetologia. 2021 Feb;64(2):313-324. doi: 10.1007/s00125-020-05317-y. Epub 2020 Nov 4. Diabetologia. 2021. PMID: 33145642 Free PMC article. Clinical Trial.
Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren's syndrome is associated with B cell hyperactivity and type I interferon activity.
Hillen MR, Urso K, Koppe E, Lopes AP, Blokland SLM, Pandit A, Slocombe T, van Maurik A, van Roon JAG, Radstake TRDJ. Hillen MR, et al. Among authors: van maurik a. RMD Open. 2020 Jun;6(2):e001184. doi: 10.1136/rmdopen-2020-001184. RMD Open. 2020. PMID: 32540951 Free PMC article. No abstract available.
Epigenetically quantified immune cells in salivary glands of Sjögren's syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology.
Blokland SLM, van Vliet-Moret FM, Hillen MR, Pandit A, Goldschmeding R, Kruize AA, Bouma G, van Maurik A, Olek S, Hoffmueller U, van Roon JAG, Radstake TRDJ. Blokland SLM, et al. Among authors: van maurik a. Rheumatology (Oxford). 2020 Feb 1;59(2):335-343. doi: 10.1093/rheumatology/kez268. Rheumatology (Oxford). 2020. PMID: 31325310 Free PMC article.
31 results